Bio-Rad Laboratories Inc. (NYSE:BIO)’s share price reached a new 52-week high on Thursday . The stock traded as high as $158.50 and last traded at $155.98, with a volume of 220,491 shares changing hands. The stock had previously closed at $145.77.

Several equities analysts recently weighed in on the company. Jefferies Group reiterated a “buy” rating on shares of Bio-Rad Laboratories in a research report on Wednesday, June 8th. Zacks Investment Research downgraded Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th.

The company’s 50 day moving average price is $143.07 and its 200-day moving average price is $138.75. The firm has a market cap of $4.56 billion and a price-to-earnings ratio of 42.39.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Wednesday, August 3rd. The company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.13 by $0.52. During the same quarter last year, the firm posted $0.97 earnings per share. The company earned $516.80 million during the quarter, compared to analysts’ expectations of $497.80 million. Bio-Rad Laboratories’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts predict that Bio-Rad Laboratories Inc. will post $3.40 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in BIO. Bank of Montreal Can increased its position in Bio-Rad Laboratories by 13.1% in the fourth quarter. Bank of Montreal Can now owns 10,021 shares of the company’s stock valued at $1,390,000 after buying an additional 1,163 shares during the last quarter. Liberty Mutual Group Asset Management Inc. raised its stake in Bio-Rad Laboratories by 51.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,320 shares of the company’s stock valued at $1,846,000 after buying an additional 4,523 shares during the last quarter. Comerica Bank raised its stake in Bio-Rad Laboratories by 0.3% in the fourth quarter. Comerica Bank now owns 15,009 shares of the company’s stock valued at $1,959,000 after buying an additional 38 shares during the last quarter. Principal Financial Group Inc. raised its stake in Bio-Rad Laboratories by 3.5% in the fourth quarter. Principal Financial Group Inc. now owns 66,434 shares of the company’s stock valued at $9,212,000 after buying an additional 2,238 shares during the last quarter. Finally, Morgan Stanley raised its stake in Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock valued at $9,921,000 after buying an additional 55,884 shares during the last quarter.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.